QR-kod

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience

BackgroundRelapsed/refractory high-risk neuroblastoma has a dismal prognosis. Anti-GD2-mediated chemo-immunotherapy has a notable anti-tumor activity in patients with relapsed/refractory high-risk neuroblastoma. The purpose of this study was to analyze the efficacy and safety of the combination of i...

Full beskrivning

Sparad:
Huvudupphov: Nur Olgun, Emre Cecen, Dilek Ince, Deniz Kizmazoglu, Birsen Baysal, Ayse Onal, Ozhan Ozdogan, Handan Guleryuz, Riza Cetingoz, Ayse Demiral, Mustafa Olguner, Ahmet Celik, Serra Kamer, Erdener Ozer, Zekiye Altun, Safiye Aktas
Materialtyp: Artigo
Språk:Inglês
Utgiven: Frontiers Media S.A. 2022-12-01
Serie:Frontiers in Oncology
Ämnen:
neuroblastoma
relapsed
refractory
dinutuximab beta
anti-GD2
Länkar:https://www.frontiersin.org/articles/10.3389/fonc.2022.1041443/full
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk